<DOC>
	<DOCNO>NCT02854397</DOCNO>
	<brief_summary>In emergency room , crucial diagnose acute attack hereditary angioedema ( HAE ) quickly provide efficient treatment . Currently , specific biomarker acute attack bradykinin-mediated angioedema help clinicians patient care . However , previous work carry purpose . All potential candidate biomarkers must validate prospective study estimate specificity sensitivity value , understand potential utility patient care . The main goal clinical trial estimate diagnostic value VE-cadherin pediatric population , differential diagnosis HAE crisis angioedema result mast cell activation crisis ( main differential diagnosis HAE ) .</brief_summary>
	<brief_title>Determination Specific Biomarkers Acute Attack Angioedema Within Pediatric Population</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<criteria>For HAE : patient document diagnosis HAE : type I ( antigenic deficiency C1 esterase inhibitor ) type II ( functional deficiency C1 esterase inhibitor ) . The existence mutation SERPING1 necessary inclusion HAE normal C1INH ( ex type III ) require mutation FXII gene typical family history HAE diagnose specialized physician belonging CREAK network . For AE result mast cell activation : document diagnosis AE result mast cell activation include : mastocytosis , chronic spontaneous urticaria , acute urticaria exposure allergen allergy challenge test , mast cell activation syndrome . For control group : compose patient present stabilized disease ( infectious , autoinflammatory inflammatory disease without implication endothelial cell ) . Over 18 year 1 year . Diagnosis HAE normal C1 esterase inhibitor AE unknown aetiology . Patients HAE receive acute attack treatment blood sample ( C1 esterase inhibitor concentrate bradykinin B2 receptor antagonist ) ; patient HAE receive prophylactic treatment ( danazol ) . Patients treat omalizumab corticosteroid treatment .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>